An updated review of the treatment landscape for advanced gastrointestinal stromal tumors

Shreyaskumar R. Patel, Peter Reichardt

Research output: Contribution to journalReview articlepeer-review


Before the introduction of tyrosine kinase inhibitors (TKIs), the overall survival of patients with advanced or metastatic gastrointestinal stromal tumors (GISTs) was 10 to 20 months because of the lack of approved therapies. In the last 20 years, a treatment algorithm for patients with advanced GISTs, which includes imatinib, sunitinib, and regorafenib as first-, second-, and third-line therapies, respectively, has been established. Recently, 2 new TKIs have been approved: ripretinib for fourth-line therapy and avapritinib as first-line therapy in patients harboring platelet-derived growth factor receptor α (PDGFRA) exon 18 D842V mutations. Additionally, there are several experimental therapies under investigation that could advance individualized patient care. All of these therapies have varying efficacies and safety profiles that warrant an updated treatment landscape review. This review article summarizes the efficacy and safety data currently available for conventional TKIs along with recently approved and experimental therapies.

Original languageEnglish (US)
Pages (from-to)2187-2195
Number of pages9
Issue number13
StatePublished - Jul 1 2021


  • avapritinib
  • gastrointestinal stromal tumor
  • imatinib
  • ripretinib
  • toxicity
  • treatment landscape
  • tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'An updated review of the treatment landscape for advanced gastrointestinal stromal tumors'. Together they form a unique fingerprint.

Cite this